Image pharmaphorum Editor R&D What’s next for oncology research? Eliminating cancer as a cause of death is a highly ambitious goal, but oncology researchers are showing no signs of giving up the fight in 2023. R&D Plotting the way forward on clinical trial diversity As the old adage goes, the first step towards solving a problem is admitting you have one. R&D Into the bowels of gut research For people living with Inflammatory Bowel Disease (IBD), navigating life around the risk of flare-ups can be a messy and exhausting challenge. R&D 12 Questions with Dr Michelle Longmire As the co-founder and chief executive officer of Medable, Dr Michelle Longmire is mission-driven to accelerate the development of new therapies for disease. Load more results
R&D What’s next for oncology research? Eliminating cancer as a cause of death is a highly ambitious goal, but oncology researchers are showing no signs of giving up the fight in 2023.
R&D Plotting the way forward on clinical trial diversity As the old adage goes, the first step towards solving a problem is admitting you have one.
R&D Into the bowels of gut research For people living with Inflammatory Bowel Disease (IBD), navigating life around the risk of flare-ups can be a messy and exhausting challenge.
R&D 12 Questions with Dr Michelle Longmire As the co-founder and chief executive officer of Medable, Dr Michelle Longmire is mission-driven to accelerate the development of new therapies for disease.
Oncology BioNTech’s ASCO 2025 oncology advances: New data on bispecif... At ASCO 2025, BioNTech presented 7 abstracts on four selected pipeline candidates in mesothelioma, lung cancer, prostate cancer, and melanoma.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
